InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,471.05
(
1.16%
)
US TECH 100
18,195.20
(
1.38%
)
Dow Jones
40,829.59
(
1.20%
)
Brent Oil
71.72
(
0.25%
)
Bitcoin
57,122.43
(
4.11%
)
Post# of 253074
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120399
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 48757

Wednesday, 06/20/2007 4:54:01 PM

Wednesday, June 20, 2007 4:54:01 PM

Post# of 253074
COLY – The wording of today’s PR (#msg-20613423) and the comments on today’s CC leave the door open a crack for PFE to continue the phase-2 trial testing PF-3512676 with Tarceva in second-line NSCLC. PFE may still be deciding what to do about this trial, which does not employ chemotherapy and hence has a somewhat different risk/benefit tradeoff than all of the other PF-3512676 trials in NSCLC.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up